CY1108538T1 - Χιμαιρικα πεπτιδια β-αμυλοειδους - Google Patents

Χιμαιρικα πεπτιδια β-αμυλοειδους

Info

Publication number
CY1108538T1
CY1108538T1 CY20071100123T CY071100123T CY1108538T1 CY 1108538 T1 CY1108538 T1 CY 1108538T1 CY 20071100123 T CY20071100123 T CY 20071100123T CY 071100123 T CY071100123 T CY 071100123T CY 1108538 T1 CY1108538 T1 CY 1108538T1
Authority
CY
Cyprus
Prior art keywords
peptide
precursor
mature protein
peptides
chimeric
Prior art date
Application number
CY20071100123T
Other languages
English (en)
Inventor
Benjamin Chain
Cheryl Fitzer-Attas
Original Assignee
Intellect Neurosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellect Neurosciences, Inc. filed Critical Intellect Neurosciences, Inc.
Publication of CY1108538T1 publication Critical patent/CY1108538T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η εφεύρεση παρέχει ένα χιμαιρικό πεπτίδιο ή μίγμα χιμαιρικών πεπτιδίων το οποίο μπορεί να διαμορφωθεί ως μία σύνθεση ανοσοποιήσεως και να χρησιμοποιηθεί σε μία μέθοδο για την ανοσοποίηση ενός θηλαστικού κατά ενός πεπτιδικού προϊόντος εσωτερικής αποκοπής προερχόμενου από μία πρόδρομη ή ώριμη πρωτεΐνη, για το οποίο το πεπτιδικό προϊόν αποκοπής και η πρόδρομη ή ώριμη πρωτεΐνη είναι εγγενή μόρια. Το χιμαιρικό πεπτίδιο ή πεπτίδια έχουν ένα επιλεκτικό του άκρου επιτόπιο κυττάρων Β, μεγέθους 2-5 αμινοξέων, από ένα φυσικά απαντώμενο πεπτιδικό προϊόν εσωτερικής αποκοπής μίας πρόδρομης ή ώριμης πρωτεΐνης, ως ελεύθερο Ν- ή C-τερματικό άκρο, συγχωνευμένο με ή χωρίς κατάλοιπα αποστάσεως με ένα επιτόπιο βοηθητικών κυττάρων Τ προερχόμενο από μία ζωντανή πηγή διαφορετική από του πεπτιδικού προϊόντος εσωτερικής αποκοπής.
CY20071100123T 1999-12-08 2007-01-29 Χιμαιρικα πεπτιδια β-αμυλοειδους CY1108538T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16968799P 1999-12-08 1999-12-08
EP00990195A EP1237930B1 (en) 1999-12-08 2000-12-08 Chimeric amyloid beta peptides

Publications (1)

Publication Number Publication Date
CY1108538T1 true CY1108538T1 (el) 2014-04-09

Family

ID=22616757

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100123T CY1108538T1 (el) 1999-12-08 2007-01-29 Χιμαιρικα πεπτιδια β-αμυλοειδους

Country Status (15)

Country Link
US (2) US7901689B2 (el)
EP (1) EP1237930B1 (el)
JP (1) JP4804690B2 (el)
CN (2) CN1414976A (el)
AT (1) ATE344803T1 (el)
AU (1) AU784925B2 (el)
CA (1) CA2393763A1 (el)
CY (1) CY1108538T1 (el)
DE (1) DE60031792T2 (el)
DK (1) DK1237930T3 (el)
ES (1) ES2275570T3 (el)
IL (2) IL149976A0 (el)
PT (1) PT1237930E (el)
WO (1) WO2001042306A2 (el)
ZA (1) ZA200205032B (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7901689B2 (en) * 1999-12-08 2011-03-08 Intellect Neurosciences, Inc. Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
KR100879810B1 (ko) 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 아밀로이드의 하향-조절을 위한 신규한 방법
IL153943A0 (en) * 2000-07-19 2003-07-31 Upjohn Co SUBSTRATES AND ASSAYS FOR beta-SECRETASE ACTIVITY
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AU2002357007A1 (en) * 2001-11-21 2003-06-10 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006508072A (ja) * 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
DE102006015001A1 (de) * 2006-03-31 2007-10-11 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Verfahren zum Nachweis und/oder zur Anreicherung von Analytproteinen und/oder Analytpeptiden aus einer komplexen Proteinmischung
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP2009538924A (ja) 2006-06-01 2009-11-12 エラン ファーマシューティカルズ，インコーポレイテッド Ａｐｐの神経活性断片
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP1944314A1 (en) * 2007-01-11 2008-07-16 Philipps-Universität Marburg Diagnosis of Alzheimer's disease and other neurodementing disorders
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
WO2009029272A2 (en) * 2007-08-27 2009-03-05 Agadjanyan Michael G Epitope vaccine for prevention and reversion of ad pathology
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0812586D0 (en) * 2008-07-09 2008-08-13 Ucl Business Plc Chimaeric peptide
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20130084245A1 (en) 2010-02-25 2013-04-04 Wyeth Llc Pet monitoring of a-beta-directed immunotherapy
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
AU2012228236B2 (en) * 2011-03-16 2016-10-27 Vivoryon Therapeutics N.V. Diagnostic antibody assay
EP2887955B1 (en) * 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
CN111051333B (zh) * 2017-08-30 2024-04-05 Km生物医薬股份公司 修饰型HSV gD蛋白及包含其的疫苗
JP2021531337A (ja) * 2018-07-12 2021-11-18 ヘキサマー・セラピューティクス・インコーポレイテッド 自己集合ペプチド骨格
CN113874078A (zh) 2019-04-05 2021-12-31 Tauc3生物制品有限公司 抗tauc3抗体及其应用
US20240226279A1 (en) * 2021-05-03 2024-07-11 Ohio State Innovation Foundation Human anti-coronavirus peptide vaccines and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018021A (en) * 1994-10-19 2000-01-25 The Research Foundation Of State University Of New York Human transaldolase: an autoantigen with a function in metabolism
AUPO390396A0 (en) * 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7901689B2 (en) * 1999-12-08 2011-03-08 Intellect Neurosciences, Inc. Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies

Also Published As

Publication number Publication date
CN1414976A (zh) 2003-04-30
DE60031792D1 (de) 2006-12-21
AU784925B2 (en) 2006-07-27
IL149976A (en) 2012-10-31
US7901689B2 (en) 2011-03-08
PT1237930E (pt) 2007-02-28
JP2003516419A (ja) 2003-05-13
DK1237930T3 (da) 2007-03-19
IL149976A0 (en) 2002-12-01
CN101935352A (zh) 2011-01-05
WO2001042306A2 (en) 2001-06-14
EP1237930B1 (en) 2006-11-08
US20110280879A1 (en) 2011-11-17
US20060088548A1 (en) 2006-04-27
ATE344803T1 (de) 2006-11-15
DE60031792T2 (de) 2007-02-22
WO2001042306A3 (en) 2001-11-01
AU2725601A (en) 2001-06-18
ZA200205032B (en) 2003-09-22
ES2275570T3 (es) 2007-06-16
CA2393763A1 (en) 2001-06-14
JP4804690B2 (ja) 2011-11-02
EP1237930A2 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
CY1108538T1 (el) Χιμαιρικα πεπτιδια β-αμυλοειδους
ES2886599T3 (es) Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
CY1105282T1 (el) Διαγνωση της κοιλιοκακης με τη χρηση ενος επιτοπιου της γλιαδινης
AU784097B2 (en) Selecting and producing T cell peptide epitopes
JP7468911B2 (ja) 腫瘍特異的抗原を特定するためのプロテオゲノミクスに基づいた方法
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
US20060111287A1 (en) Acetylated protein
ATE429448T1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
Werkmeister et al. The effect of sequence variations and structure on the cytolytic activity of melittin peptides
Eastman et al. A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex‐specific monoclonal antibody
AU2011289426A1 (en) Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
CY1116756T1 (el) Αιμοκυανινη και κωδικευουσα γι'αυτην ακολουθια νουκλεϊνικου οξεος
ATE230026T1 (de) Menschliches wachstumsgen und minderwuchse gen bereich
EP1752472A3 (en) Chimeric amyloid beta peptides
JP2013078325A (ja) Ｈｌａ結合性ペプチド、その前駆体、それをコードするｄｎａ断片および組み換えベクター
Manea et al. Design, structural, and immuno‐analytical properties of antigenic bioconjugates comprising a β‐amyloid‐plaque specific epitope
JP5648927B2 (ja) Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
EP3008085A2 (en) Anti-factor viii antibodies or uses thereof
KR101116872B1 (ko) 면역원성이 증가된 펩티드 항원 및 이를 생산하는 방법
Wipke Epitope immunodominance and the murine cytotoxic T lymphocyte response to Listeria monocytogenes
JP2010285418A (ja) 有機硝酸系爆発物に対する抗体およびその製作方法
Garg Role of cytosolic chaperone HSP90 (HSP90AA1/AB1) in antigen presentation by MHC I molecules
Ogun et al. The oligomerization domain of C4-binding protein acts as an adjuvant: a fusion protein of MSP119 with the murine C4bp domain protects mice against malaria.
BR112017000428B1 (pt) Produto imunogênico com base em sequências de aminoácidos muteína amiloide beta, composição compreendendo o produto e uso do mesmo para tratar ou prevenir amiloidose